Multi-Kinase Inhibitors

被引:65
作者
Garuti, Laura [1 ]
Roberti, Marinella [1 ]
Bottegoni, Giovanni [2 ]
机构
[1] Univ Bologna, Dept Pharm & Biotechnol, I-40126 Bologna, Italy
[2] Italian Inst Technol, Dept Drug Discovery & Dev, I-16163 Genoa, Italy
关键词
ATP-competitive; biological activity; heterocycles; inhibition; irreversible inhibitors; kinase; multi-target; SAR; ENDOTHELIAL GROWTH-FACTOR; STRUCTURE-BASED DESIGN; POTENT AURORA KINASE; DUAL INHIBITORS; PHASE-I; BIOLOGICAL EVALUATION; DOSE-ESCALATION; SMALL-MOLECULE; PD; 0332991; VEGFR2;
D O I
10.2174/0929867321666141216125528
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The limitations of many mono-kinase inhibitors can be overcome by agents with multi-target action. An important advantage of targeting more than one kinase, is an increase in potency, due to the synergistic effect. Moreover, this approach can reduce the possibility of developing drug resistance. Several multitarget agents have been designed as single kinase inhibitors and found to be multi-target inhibitors because of the structural homology among the ATP-binding site of kinases. In other cases, these inhibitors have been obtained by optimization of potent individual inhibitors or by combination of selective ligands. Also some irreversible inhibitors act on different kinases and covalently modify the cysteine residues located near the ATP-binding pocket. In this review the most recent examples of multi-kinase inhibitors are reported, focusing on chemical structures, structure-activity relationship (SAR) and biological activity. These inhibitors, suitably substituted, could be used in designing other multitarget agents. Virtual molecular docking would suggest potential targets of molecules, moreover combining pharmacophore combination and screening methods could probably help in the discovery of more potent multikinase inhibitors.
引用
收藏
页码:695 / 712
页数:18
相关论文
共 71 条
[1]   Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein [J].
Aertgeerts, Kathleen ;
Skene, Robert ;
Yano, Jason ;
Sang, Bi-Ching ;
Zou, Hua ;
Snell, Gyorgy ;
Jennings, Andy ;
Iwamoto, Keiji ;
Habuka, Noriyuki ;
Hirokawa, Aki ;
Ishikawa, Tomoyasu ;
Tanaka, Toshimasa ;
Miki, Hiroshi ;
Ohta, Yoshikazu ;
Sogabe, Satoshi .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (21) :18756-18765
[2]   Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors [J].
Awada, A. H. ;
Dumez, H. ;
Hendlisz, A. ;
Wolter, P. ;
Besse-Hammer, T. ;
Uttenreuther-Fischer, M. ;
Stopfer, P. ;
Fleischer, F. ;
Piccart, M. ;
Schoffski, P. .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (03) :734-741
[3]   Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase [J].
Awazu, Yoshiko ;
Mizutani, Akio ;
Nagase, Yoshinori ;
Tsuchiya, Shuntarou ;
Nakamura, Kazuhide ;
Kakoi, Yuichi ;
Kitahara, Osamu ;
Takeuchi, Toshiyuki ;
Yamasaki, Seiji ;
Miyamoto, Naoki ;
Iwata, Hidehisa ;
Miki, Hiroshi ;
Imamura, Shinichi ;
Hori, Akira .
CANCER SCIENCE, 2013, 104 (04) :486-494
[4]   FLT3/D835Y mutation knock-in mice display less aggressive disease compared with FLT3/internal tandem duplication (ITD) mice [J].
Bailey, Emily ;
Li, Li ;
Duffield, Amy S. ;
Ma, Hayley S. ;
Huso, David L. ;
Small, Don .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (52) :21113-21118
[5]   Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks [J].
Barf, Tjeerd ;
Kaptein, Allard .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (14) :6243-6262
[6]   Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors [J].
Baska, F. ;
Szabadkai, I. ;
Sipos, A. ;
Breza, N. ;
Szantai-Kis, C. ;
Kekesi, L. ;
Garamvoelgyi, R. ;
Nemes, Z. ;
Baska, F. ;
Neumann, L. ;
Torka, R. ;
Ullrich, A. ;
Keri, G. ;
Orfi, L. .
CURRENT MEDICINAL CHEMISTRY, 2014, 21 (17) :1938-1955
[7]   Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia [J].
Bavetsias, Vassilios ;
Crumpler, Simon ;
Sun, Chongbo ;
Avery, Sian ;
Atrash, Butrus ;
Faisal, Amir ;
Moore, Andrew S. ;
Kosmopoulou, Magda ;
Brown, Nathan ;
Sheldrake, Peter W. ;
Bush, Katherine ;
Henley, Alan ;
Box, Gary ;
Valenti, Melanie ;
Brandon, Alexis de Haven ;
Raynaud, Florence I. ;
Workman, Paul ;
Eccles, Suzanne A. ;
Bayliss, Richard ;
Linardopoulos, Spiros ;
Blagg, Julian .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (20) :8721-8734
[8]   Imidazo[4,5-b]pyridine Derivatives As Inhibitors of Aurora Kinases: Lead Optimization Studies toward the Identification of an Orally Bioavailable Preclinical Development Candidates [J].
Bavetsias, Vassilios ;
Large, Jonathan M. ;
Sun, Chongbo ;
Bouloc, Nathalie ;
Kosmopoulou, Magda ;
Matteucci, Mizio ;
Wilsher, Nicola E. ;
Martins, Vanessa ;
Reynisson, Johannes ;
Atrash, Butrus ;
Faisal, Amir ;
Urban, Frederique ;
Valenti, Melanie ;
Brandon, Alexis de Haven ;
Box, Gary ;
Raynaud, Florence I. ;
Workman, Paul ;
Eccles, Suzanne A. ;
Bayliss, Richard ;
Blagg, Julian ;
Linardopoulos, Spiros ;
McDonald, Edward .
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (14) :5213-5228
[9]   The Role of FLT3 Kinase as an AML Therapy Target [J].
Beffinger, Micha ;
Skwarska, Anna .
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (19) :2758-2765
[10]   Cancer Multitarget Pharmacology in Prostate Tumors: Tyrosine Kinase Inhibitors and Beyond [J].
Bologna, M. ;
Vicentini, C. ;
Muzi, P. ;
Pace, G. ;
Angelucci, A. .
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (19) :2827-2835